• Teewinot Life Sciences Corporation Announced Today Grant Of A Canadian Patent With Broad Claims To Biosynthetic Production Of Cannabinoids

    • September 7, 2018
    • Posted By : admin
    • 0 Comment
    •   126 views

    Teewinot Life Sciences Corporation, a global leader in the production of cannabinoids for use in the pharmaceutical and nutraceutical markets, and its wholly owned Irish subsidiary Teewinot Technologies, Ltd, announced today the grant of Canadian Patent No. 2 902 452 (“the ‘452 patent”). The ‘452 patent has broad claims to biosynthetic methods for the production of cannabinoids, cannabinoid prodrugs and cannabinoid analogs.

    Dr. Richard Peet, Teewinot’s Executive Vice President, stated that “with the grant of the ‘452’ patent, Teewinot is well positioned to compete in the important Canadian nutraceutical and pharmaceutical markets. Teewinot is the only company capable of producing large quantities of naturally-occurring cannabinoids that are only produced in the plant in small quantities such as CBCA and varin series of cannabinoids. The ‘452 patent is the first Canadian patent covering biosynthetic production of novel cannabinoids, cannabinoid prodrugs and cannabinoid analogs by means of biocatalysis and synthetic biology. Teewinot has a large portfolio patents in the U.S., and in key countries around the world, with claims covering biosynthetic production of cannabinoids. These biosynthetic processes provide Teewinot with the capability of cost-effectively producing 18 naturally-occurring cannabinoids in pharmaceutically pure form and in large quantities, without having to cultivate the Cannabis plant.”

    Charlie Brink, Teewinot’s Chairman, stated “we are happy to announce the issuance of the ‘452’ patent as it’s the first Canadian patent covering biosynthetic production of novel cannabinoids, cannabinoid prodrugs and cannabinoid analogs by means of biocatalysis and synthetic biology. Teewinot has demonstrated that these proprietary equipment and methods improve a wide range of production metrics, and we look forward to partnering with customers that could benefit from these advantages in the global marketplace.”

  126 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!